target identification

AffinityLigand provides solution-based Affinity Selection–Mass Spectrometry (AS-MS) for protein–ligand binding studies through its Bind2Biology™ platform. The company offers binder screening, affinity ranking, target identification, complex analysis, and binding mechanism studies.

affinity rankingAffinity Selection–Mass Spectrometry (AS-MS)binder screeningbinding mechanism studiescomplex analysis

AltraBio is a contract research company specializing in advanced biological data analysis and bioinformatics services, helping biopharma, cosmetic, and clinical R&D organizations extract insights from cytometry, omics, and medical data using AI, machine learning, and biostatistics. It serves pharmaceutical companies, biotech startups, dermo-cosmetic leaders, and university hospitals worldwide.

automated gatingbioinformatics pipeline developmentbiomarker discoverybiostatisticsbulk transcriptomicscytometry data analysishigh-dimensional panel analysismachine learningpatient stratificationproteomicsreal-world data miningsingle-cell RNA-seq analysisstatistical modeling

CDI Labs provides proteomic products and services for autoantibody profiling, biomarker discovery, target identification, and antibody development. Its platforms include the HuProt™ Human Proteome Microarray (21,000+ full-length human proteins) and PhIP-Seq services such as HuScan®, MouseScan™, VirScan®, and VirScan® Exposome. The company also offers specialized CRO services including antibody development, protein production, cell therapy, and immunogenicity testing.

antibody developmentbiomarker discoverycell therapyCRISPR-Cas9 immunogenicity testingdiagnostic developmentimmunogenicity testingmolecular glue discoverypan-proteome epitope mappingPhIP-Seqpost-translational modification specificity profilingprotein microarrayprotein productionproteome-wide autoantibody profiling

Fauna Bio is an AI-driven drug discovery company leveraging data from 100 million years of evolved disease resistance in mammals. Using its exclusive biobank of genetic data and its in-house Convergence™ platform, it replicates how extreme animal models resist disease to create new drugs for humans. It has a multi-year $494M agreement with Eli Lilly for preclinical drug discovery in obesity, and runs space-focused research programs on hibernation and radiation protection.

AI-driven drug discoverycomputational biologyConvergence™ AI platformgenetic data biobankin-vivo experimentspreclinical drug discovery

Integral Molecular is a research-driven biotechnology company creating innovative technologies and therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes. Founded in 2001, it has developed 6 novel technology platforms and provides services such as antibody specificity screening, target identification, epitope mapping, and antibody discovery.

Ala-scan epitope mappingantibody discoveryantibody specificity screeningCDR-scanningcell and molecular biologyepitope mappingFlow Cytometryhigh-throughput instrumentationrobotics